Ben Hunt is a product analyst at Sleuth Insights, where he covers metabolic disease and T-cell and cell therapies. He writes Sleuth's quarterly intelligence reports on GLP-1 and metabolic drugs, T-cell engagers and in vivo cell therapy, and delivers Sleuth Concierge engagements for clients. Before Sleuth he was an analyst in the pricing and market access practice at ClearView Healthcare Partners, a life sciences strategy consultancy. He holds an S.B. in chemistry from the University of Chicago.
